Jaguar Health Files 8-K on Definitive Agreement & Equity Sales
Ticker: JAGX · Form: 8-K · Filed: 2025-02-04T00:00:00.000Z
Sentiment: neutral
Topics: definitive-agreement, financial-obligation, equity-sale
Related Tickers: JAGX
TL;DR
Jaguar Health inked a new deal, creating financial obligations and selling more stock.
AI Summary
On January 28, 2025, Jaguar Health, Inc. entered into a material definitive agreement related to the creation of a direct financial obligation. The company also reported on unregistered sales of equity securities. This filing includes financial statements and exhibits.
Why It Matters
This filing indicates new financial obligations and equity transactions for Jaguar Health, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details new financial obligations and unregistered equity sales, which can introduce financial risk and dilution.
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36714 (commission_file_number) — SEC File Number
FAQ
What is the nature of the material definitive agreement Jaguar Health entered into?
The filing indicates the entry into a material definitive agreement that resulted in the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on January 28, 2025.
What other significant event is reported in this 8-K filing besides the definitive agreement?
The filing also reports on unregistered sales of equity securities by the company.
What is the state of incorporation for Jaguar Health, Inc.?
Jaguar Health, Inc. is incorporated in Delaware.
What is the SEC file number for Jaguar Health, Inc.?
The SEC file number for Jaguar Health, Inc. is 001-36714.
Filing Stats: 745 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2025-02-03 18:18:10
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital M
- $6,220,812.50 — ote in the original principal amount of $6,220,812.50 (as amended, the "Note") issued by Borr
- $1,094,952 — stock to such holder in exchange for a $1,094,952 reduction in the outstanding balance of
Filing Documents
- d842829d8k.htm (8-K) — 27KB
- d842829dex41.htm (EX-4.1) — 16KB
- g842829g57d67.jpg (GRAPHIC) — 4KB
- 0001193125-25-019416.txt ( ) — 174KB
- jagx-20250128.xsd (EX-101.SCH) — 3KB
- jagx-20250128_lab.xml (EX-101.LAB) — 18KB
- jagx-20250128_pre.xml (EX-101.PRE) — 11KB
- d842829d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: President and Chief Executive Officer Date: February 3, 2025